Are you at risk for colorectal cancer? Answer these 13 questions in less than 1 minute to find out.
Our Clinical Trial Finder is a one-stop place to find and learn more about high-impact research studies for patients with advanced CRC. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status.
Our Path to a Cure report is our plan for the future. This plan is not just for Fight CRC, but for everyone who is willing to champion this cause.
Shop our online store to raise awareness everywhere you go! From t-shirts and fanny packs to patient education resources, we have a little bit of everything.
Raise Awareness. Be an Advocate. Host an Event.
Program Status Clinical trial’s patient recruitment status
Phase Phase of the clinical trial that is recruiting (I, II, or III)
Immunotherapy-centered Trial A flag to indicate whether the trial is an immunotherapy trial
Prior Immunotherapy Allowed Whether the clinical trial is open to patients who have received prior immunotherapy
CRC-directed Trial A flag to indicate whether the trial is specifically targeting colon cancer, rectal cancer, or colorectal cancer patients
Drugs Therapeutics used in the clinical trial
Tags
Comments
Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, Opdivo, BMS-936558)
Inclusion Criteria
Inclusion Criteria:
For Dose escalation: subjects with cervical, ovarian, bladder and colorectal cancer (CRC), head and neck, gastric and hepatocellular cancer naive to immuno-oncology agents; 1st line melanoma and 1st line/2nd line NSCLC; Renal Cell Carcinoma naive to IO; NSCLC progressing while on or after therapy with anti-PD1/anti-PDL-1 and melanoma subjects progressed while-on or after treatment with anti-PD1 or anti-PDL1 with or without anti-CTLA-4. For Dose Expansion: all of the above in escalation except for cervical, ovarian, and CRC Progressed, or been intolerant to, at least one standard treatment regimen, except for participants in 1st line cohorts. ECOG performance status between 0 and 2 At least 1 lesion with measurable disease at baseline Availability of an existing tumor biopsy sample (and consent to allow pre-treatment tumor biopsy)
Exclusion Criteria
Exclusion Criteria:
Primary central nervous system (CNS) tumors or solid tumors with CNS metastases as the only site of active disease Autoimmune disease Encephalitis, meningitis, or uncontrolled seizures in the year prior to informed consent Uncontrolled CNS metastases
Other protocol defined inclusion/exclusion criteria could apply
NCT ID Trial ID number from clinicaltrials.gov or other database
Date Trial Added Date on which the clinical trial was added to the clinicaltrials.gov website
Updated Date Date on which the clinical trial was updated on the clinicaltrials.gov website